Sarfraz Muhammad Haroon, Haq Rana Intisar Ul, Mehboob Mohammad Asim
Dr. Muhammad Haroon Sarfraz, MBBS. Armed Forces Institute of Ophthalmology, Rawalpindi, Pakistan.
Dr. Rana Intisar Ul Haq, MCPS(Ophth), FCPS(Ophth). Armed Forces Institute of Ophthalmology, Rawalpindi, Pakistan.
Pak J Med Sci. 2017 Jan-Feb;33(1):210-214. doi: 10.12669/pjms.331.11644.
To determine the efficacy of topical Nepafenac (0.1%), administered post-operatively in prevention of Macular Edema (ME), after cataract surgery in patients with Non-Proliferative Diabetic Retinopathy (NPDR).
This randomized control trial was conducted at Armed Forces Institute of Ophthalmology (AFIO), Rawalpindi from Sep 2015 to Sep 2016. Sixty eyes of 60 patients with NPDR underwent phacoemulsification with intraocular lens implantation. Group 1 received 0.1% Nepafenac, 8-hourly, in operated eye after cataract surgery for three months, along with routine post-operative medications. Group-2 received only routine post-operative medications. ME was defined as increase in Central Macular Thickness (CMT) of >10% from pre-operative baseline, measured using spectral domain optical coherence tomography.
Mean age of study population was 60.97±4.91 years. Out of 60 patients, 34 (56.7%) were males and 24 (43.3%) were females. Mean pre-operative CMT, 3 months post-operative CMT, mean change in CMT and mean frequency change in CMT of Group-1 was 226.5±10.86µm, 228.83±14.56 µm, 2.33±10.45 µm and 1.05% respectively. Mean pre-operative CMT, three months post-operative CMT, mean change in CMT and mean frequency change in CMT in Group-2 was 223.93±11.69µm, 236.17±16.16 µm, 12.23±12.40µm and 5.51% respectively. ME was observed in one patient (3.3%) in Group-1, and seven patients (23.3%) in Group 2. The difference of mean change in CMT and frequency change in CMT between groups was statistically significant (p<0.05).
0.1% topical Nepafenac is effective in prevention of macular edema after cataract surgery in patients with non-proliferative diabetic retinopathy (NPDR).
确定术后局部应用0.1%奈帕芬酸对非增殖性糖尿病视网膜病变（NPDR）患者白内障手术后黄斑水肿（ME）的预防效果。
本随机对照试验于2015年9月至2016年9月在拉瓦尔品第武装部队眼科研究所（AFIO）进行。60例NPDR患者的60只眼接受了白内障超声乳化联合人工晶状体植入术。第1组在白内障手术后3个月，患眼每8小时接受一次0.1%奈帕芬酸治疗，同时给予常规术后药物治疗。第2组仅接受常规术后药物治疗。ME定义为使用光谱域光学相干断层扫描测量的中心黄斑厚度（CMT）较术前基线增加>10%。
研究人群的平均年龄为60.97±4.91岁。60例患者中，男性34例（56.7%），女性24例（43.3%）。第1组术前平均CMT、术后3个月平均CMT、CMT平均变化和CMT平均频率变化分别为226.5±10.86µm、228.83±14.56 µm、2.33±10.45 µm和1.05%。第2组术前平均CMT、术后3个月平均CMT、CMT平均变化和CMT平均频率变化分别为223.93±11.69µm、236.17±16.16 µm、12.23±12.40µm和5.51%。第1组有1例患者（3.3%）出现ME，第2组有7例患者（23.3%）出现ME。两组之间CMT平均变化和CMT频率变化的差异具有统计学意义（p<0.05）。
0.1%局部应用奈帕芬酸对非增殖性糖尿病视网膜病变（NPDR）患者白内障手术后黄斑水肿的预防有效。
